Rapid microbiology testing market seen reaching $16.91 billion by 2035

Market Research Future projects the global rapid microbiology testing market will grow from $7.11 billion in 2026 to $16.91 billion by 2035. Growth is being driven by FDA regulatory changes, pharma lab automation and the shift from slow culture methods to faster molecular and automated testing.

Why it matters: - Rapid microbiology testing is moving from a niche workflow upgrade to a core requirement in clinical, pharmaceutical and food-safety labs. - Faster detection can cut identification and sterility-confirmation times from days to hours, which affects treatment decisions, manufacturing release cycles and contamination control. - Regulatory pressure from the FDA, WHO and European authorities is making rapid methods less optional and more operationally necessary.

What happened: - Market Research Future projects the global rapid microbiology testing market will rise from USD 7.11 billion in 2026 to USD 16.91 billion by 2035. - The forecast implies a 10.1% CAGR for 2026 to 2035. - The market was estimated at USD 6.46 billion in 2025. - The report points to FDA mass-spectrometry reclassification and pharma lab automation as key growth catalysts. - The report includes a sample request link: Request a free sample.

The details: - The FDA reclassified clinical mass-spectrometry systems to Class II device status in 2025 under 21 CFR 866.2300. - That shift uses a 510(k) pathway instead of full premarket approval for those systems. - The reclassification is expected to accelerate MALDI-TOF adoption by 25% to 30% across U.S. clinical labs. - MALDI-TOF can identify bacteria with more than 94% accuracy in under 10 minutes. - Traditional biochemical identification workflows often take 48 to 72 hours. - WHO revised Annex 1 sterile-manufacturing guidance to require faster release cycles across aseptic manufacturing facilities. - European Medicines Agency Annex 1 enforcement requires full compliance by 2025. - Pharmaceutical companies invested more than USD 3.2 billion collectively in total laboratory automation from 2023 to 2025. - The report says 60% to 80% of health laboratory work can be automated. - Automated processing can reduce common analytical errors from about 8% to 1%. - Automated blood-culture systems have shortened detection windows from days to hours. - Rapid identification paired with reflex antimicrobial susceptibility testing can cut time to targeted therapy from 48 to 72 hours to under 18 hours. - The report says the WHO identifies antimicrobial resistance as a major threat tied to more than 1.2 million global deaths annually. - A UN target aims for a 10% reduction in resistance-related mortality by 2030. - The report says lateral-flow immunoassays support low-cost point-of-care testing without lab infrastructure. - bioMérieux acquired Accellix in January 2026 to add rapid flow cytometry for cell and gene therapy quality control. - More details are available in the full report.

Between the lines: - The market growth case is driven more by regulation and workflow economics than by discretionary spending. - Pharma QC appears to be becoming a bigger profit pool because sterile manufacturing and cell therapy need faster release testing. - The report's segment data shows recurring consumables sales remain important, but instruments are the fastest-growing product category. - Nucleic acid-based methods still dominate, while immunological methods are gaining from decentralized testing demand. - Clinical diagnostics remains the largest application, but pharmaceutical and biotech quality control is the fastest-growing use case. - North America leads the market, while Asia-Pacific is the fastest-growing region. - The report says the competitive field is moderately concentrated, with the top five players holding an estimated 52% to 58% of global revenue. - The report places bioMérieux, BD, Thermo Fisher Scientific, Charles River Laboratories and Merck KGaA among the leading players.

What's next: - By 2030, the report expects AI-powered microbial identification and predictive analytics to become more common in rapid microbiology workflows. - Cloud-native analytics may create recurring software revenue for vendors alongside hardware sales. - Next-generation sequencing could become a routine diagnostic tool in the early 2030s as costs fall. - The report says whole-genome sequencing costs fell below USD 200 per sample in 2024 and could reach USD 50 by 2030. - At that level, metagenomic sequencing could become viable for routine infection diagnostics. - That shift would expand demand for library-preparation consumables, bioinformatics software and sample-prep automation.

The bottom line: - Rapid microbiology testing is becoming a compliance-driven, automation-led market with long runway growth through 2035.